International Stem Cell Corporation (ISCO) is a biotechnology company. The Company is focused on therapeutic and biomedical product development. The Company's segments include Therapeutic Market, Cosmetic Market and Biomedical Market. The Company's subsidiaries include International Stem Cell Corporation, a research and development company, for the Therapeutic Market for clinical applications of human parthenogenetic stem cells (hpSCs) for the treatment of various diseases, such as Parkinson's disease, liver diseases and corneal blindness; Cyto Therapeutics, PTY LTD, a research and development company, for the Therapeutic Market; Lifeline Skin Care, Inc. for the Cosmetic Market, which develops, manufactures and markets a category of cosmetic skin care products based on biotechnology with human stem cells, and Lifeline Cell Technology, LLC for the Biomedical Market, which develops, manufactures and commercializes primary human cell research products.
Industry, Sector and Symbol:
Capitalization:- Market Cap: $5.81 million
- Outstanding Shares: 4,004,000
Average Prices:- 50 Day Moving Avg: $1.21
- 200 Day Moving Avg: $1.37
- 52 Week Range: $0.65 - $2.50
P/E:- Trailing P/E Ratio: 0.50
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $7.55 million
- Price / Sales: 0.79
- Book Value: $0.16 per share
- Price / Book: 9.31
Profitability:- EBIDTA: ($4,000,000.00)
- Net Margins: 137.81%
- Return on Equity: 1,193.12%
- Return on Assets: 137.47%
Debt:- Current Ratio: 0.45%
- Quick Ratio: 0.26%
Misc:- Average Volume: 3,352 shs.
- Beta: 0.17
Frequently Asked Questions for International Stem Cell Corp. (OTCMKTS:ISCO)
What is International Stem Cell Corp.'s stock symbol?
International Stem Cell Corp. trades on the OTCMKTS under the ticker symbol "ISCO."
How were International Stem Cell Corp.'s earnings last quarter?
International Stem Cell Corp. (OTCMKTS:ISCO) issued its earnings results on Wednesday, May, 17th. The company reported ($0.78) earnings per share (EPS) for the quarter. The business had revenue of $2.01 million for the quarter. International Stem Cell Corp. had a return on equity of 1,193.12% and a net margin of 137.81%. View International Stem Cell Corp.'s Earnings History.
Who are some of International Stem Cell Corp.'s key competitors?
Some companies that are related to International Stem Cell Corp. include Bio Blast Pharma (ORPN), Dextera Surgical (DXTR), Lombard Medical (EVAR), Transgenomic (PRPO), Relmada Therapeutics (RLMDD), Valeritas Holdings (VLRX), Mateon Therapeutics (MATN), Dipexium Pharmaceuticals (PLXP), Ritter Pharmaceuticals (RTTR), Kitov Pharmaceuticals Holdings (KTOV), Celsion Corporation (CLSN), Opexa Therapeutics (OPXA), Acura Pharmaceuticals (ACUR), Strata Skin Sciences (SSKN), Rosetta Genomics (ROSG), NeuroMetrix (NURO), Critical Outcome T (COTQF) and Windtree Therapeutics (WINT).
Who are International Stem Cell Corp.'s key executives?
International Stem Cell Corp.'s management team includes the folowing people:
- Andrey Semechkin Ph.D., Co-Chairman of the Board, Chief Executive Officer
- Donald Arthur Wright, Independent Co-Chairman of the Board
- Mahnaz Ebrahimi, Chief Financial Officer, Secretary
- Russell Kern Ph.D., Executive Vice President, Chief Scientific Officer
- Charles J. Casamento, Executive Director and Principal, The Sage Group
- Paul V. Maier, Independent Director
How do I buy International Stem Cell Corp. stock?
Shares of International Stem Cell Corp. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is International Stem Cell Corp.'s stock price today?
One share of International Stem Cell Corp. stock can currently be purchased for approximately $1.49.
MarketBeat Community Rating for International Stem Cell Corp. (OTCMKTS ISCO)MarketBeat's community ratings are surveys of what our community members think about International Stem Cell Corp. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for International Stem Cell Corp. (OTCMKTS:ISCO) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for International Stem Cell Corp. (OTCMKTS:ISCO)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for International Stem Cell Corp. (OTCMKTS:ISCO)Earnings History by Quarter for International Stem Cell Corp. (OTCMKTS ISCO)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/17/2017 | Q1 2017 | | ($0.78) | | $2.01 million | View | N/A |  |
| 11/14/2016 | Q3 2016 | | ($0.30) | | $1.94 million | View | N/A | |
| 11/13/2014 | Q3 2014 | ($0.01) | ($0.01) | $1.90 million | $1.96 million | View | N/A | |
| 8/12/2014 | Q2 2014 | ($0.01) | ($0.01) | $1.85 million | $1.59 million | View | N/A | |
| 11/13/2013 | | | ($0.03) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for International Stem Cell Corp. (OTCMKTS:ISCO)No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for International Stem Cell Corp. (OTCMKTS:ISCO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for International Stem Cell Corp. (OTCMKTS:ISCO)Insider Ownership Percentage: 82.32%
Insider Trades by Quarter for International Stem Cell Corp. (OTCMKTS:ISCO)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/22/2017 | Andrey Semechkin | CEO | Buy | 3,200 | $1.64 | $5,248.00 | |
| 3/22/2017 | Andrey Semechkin | CEO | Buy | 10,000 | $1.67 | $16,700.00 | |
| 3/14/2017 | Andrey Semechkin | CEO | Buy | 8,100 | $1.41 | $11,421.00 | |
| 12/8/2016 | Andrey Semechkin | CEO | Buy | 285,714 | $1.75 | $499,999.50 | |
| 9/14/2016 | Andrey Semechkin | CEO | Buy | 200,000 | $1.75 | $350,000.00 | |
| 8/22/2016 | Andrey Semechkin | CEO | Buy | 154,285 | $1.75 | $269,998.75 | |
| 6/29/2016 | Andrey Semechkin | CEO | Buy | 215,000 | $1.75 | $376,250.00 | |
| 8/6/2014 | Ruslan Semechkin | Major Shareholder | Buy | 1,000,000 | $0.10 | $100,000.00 | |
| 1/22/2013 | Andrey Semechkin | CEO | Buy | 10,000,000 | $0.20 | $2,000,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for International Stem Cell Corp. (OTCMKTS:ISCO)
Latest Headlines for International Stem Cell Corp. (OTCMKTS:ISCO)
| Source: |
|
| Date | Headline |
|---|
 | International Stem Cell Corp. :ISCO-US: Earnings Analysis: Q1, 2017 By the Numbers : June 13, 2017
finance.yahoo.com - June 13 at 10:50 AM |
 | International Stem Cell Corp (ISCO) Issues Earnings Results
www.americanbankingnews.com - May 18 at 10:44 AM |
| International Stem Cell Corporation Announces Operating Results for the Quarter ended March 31, 2017
finance.yahoo.com - May 17 at 9:54 AM |
 | BRIEF-International Stem Cell receives approval to start second patient cohort in clinical trial for Parkinson’s disease
www.reuters.com - May 11 at 11:35 PM |
 | Stem Cells Market 2022 Global Trends and Analysis Research Report Now Available at ReportsnReports.com
www.marketwatch.com - May 11 at 11:35 PM |
| International Stem Cell Corporation Receives Approval to Start Second Patient Cohort in Clinical Trial for Parkinson’s Disease
finance.yahoo.com - May 9 at 12:19 PM |
| International Stem Cell Corporation to Present Results of Neural Stem Cell Transplantation for Parkinson's Disease at the ASGCT 2017 Annual Meeting
finance.yahoo.com - May 4 at 11:31 AM |
 | 3 Things In Biotech You Should Learn Today: April 27, 2017
seekingalpha.com - April 28 at 6:57 PM |
| International Stem Cell Corporation Completes First Cohort In Parkinson's Disease Clinical Trial
finance.yahoo.com - April 25 at 10:39 AM |
| International Stem Cell Corporation Announces 2016 Fourth Quarter and Year-End Results
finance.yahoo.com - April 7 at 10:32 AM |
| International Stem Cell Corp. :ISCO-US: Earnings Analysis: Q4, 2016 By the Numbers : April 5, 2017
finance.yahoo.com - April 7 at 10:32 AM |
| INTERNATIONAL STEM CELL CORP Files SEC form 10-K, Annual Report
biz.yahoo.com - March 31 at 6:00 PM |
| International Stem Cell Corp (ISCO) CEO Andrey Semechkin Purchases 10,000 Shares
www.americanbankingnews.com - March 22 at 8:34 PM |
| Insider Buying: International Stem Cell Corp (ISCO) CEO Purchases 8,100 Shares of Stock
www.americanbankingnews.com - March 15 at 12:24 AM |
| INTERNATIONAL STEM CELL CORP Files SEC form 8-K, Entry into a Material Definitive Agreement
biz.yahoo.com - March 1 at 11:39 AM |
| International Stem Cell Corporation Announces Third Patient with Parkinson's Disease in Phase I Clinical Trial
finance.yahoo.com - February 28 at 9:23 AM |
| INTERNATIONAL STEM CELL CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and
biz.yahoo.com - January 18 at 6:31 PM |
| International Stem Cell Corporation Announces Second Patient with Parkinson’s Disease Treated in Phase I Clinical Trial
finance.yahoo.com - December 7 at 6:07 PM |
| International Stem Cell Corporation Announces Second Patient with Parkinson's Disease Treated in Phase I Clinical Trial
finance.yahoo.com - December 7 at 6:07 PM |
| BRIEF-International Stem Cell Q3 revenue falls 9 pct to $1.94 mln
www.reuters.com - November 16 at 5:57 PM |
| International Stem Cell Corporation Announces Operating Results for the Three and Nine-months ended September …
finance.yahoo.com - November 16 at 9:18 AM |
| International Stem Cell Corporation to Present Results of Neural Stem Cell Transplantation for Parkinson’s Disease at the Neuroscience 2016 Conference
finance.yahoo.com - November 10 at 5:12 PM |
| International Stem Cell Corporation Publishes Results of Safety Studies Conducted in Support of the First Human Pluripotent Stem Cell Based Therapy for Parkinson’s Disease
finance.yahoo.com - October 5 at 10:54 AM |
| International Stem Cell Corp (ISCO) CEO Andrey Semechkin Bought $350,000 of Shares
finance.yahoo.com - September 15 at 6:06 PM |
 | Edison Issues Update on International Stem Cell (ISCO)
www.prnewswire.com - August 2 at 10:30 AM |
 | ISC-hpNSC transplantation is being evaluated for the treatment of Parkinson’s Disease
globenewswire.com - July 28 at 8:45 AM |
| International Stem Cell Corporation Announces Successful Cell Transplantation for the First Patient in Phase 1 Clinical Trial of ISC-hpNSC
finance.yahoo.com - July 28 at 8:30 AM |
 | Stem Cell Partnership: Patient Advocates And Scientists At The International Society For Stem Cell Research Convention
www.huffingtonpost.com - July 10 at 5:17 PM |
| INTERNATIONAL STEM CELL CORP Files SEC form 8-K, Unregistered Sale of Equity Securities
biz.yahoo.com - July 6 at 2:08 PM |
| International Stem Cell Corp (ISCO.PK)
www.reuters.com - June 17 at 5:36 PM |
International Stem Cell Corp. (ISCO) Chart for Friday, July, 28, 2017
